HEALTH CARE POLICY AND LAW

Association of Ontario's Ban on Menthol Cigarettes With Smoking Behavior 1 Month After Implementation
The province of Ontario, Canada, implemented a full menthol cigarette ban on January 1, 2017. To date, there has been no population-wide, systematic evaluation of the associat i o n o f t h e i m p l e m e n t a t i o n o f a m e n t h o l b a n with smoker behavior. Assessments of perceived behavioral responses to hypothetical menthol flavor bans are useful 1 ;
however, there is no guarantee that individuals will follow through with their planned behaviors. This study compares respondents' planned behavior before the ban with actual behavior 1 month after the ban.
Methods | Eligible participants were residents of Ontario 16 years or older who had smoked at least 1 menthol cigarette in the past year and were past-month smokers. A total of 325 participants were recruited using random-digit dialing of residential telephone numbers from September 12 through December 31, 2016. Participation rate for the random-digit dialing was 44.1%, with a 6.7% refusal rate among known eligible participants, consistent with an established provincial health monitoring survey. Participants were contacted for follow-up beginning 1 month (Februar y 1, 2017) after the implementation of the b a n ( J a n u a r y 1 , 2 0 1 7 ) t h r o u g h a n o n l i n e s u r v e y (206 recontacted [63.4%]). Those who were unavailable for follow-up did not differ by level of menthol smoking, age, sex, income, educational level, or smoking characteristics. Planned reaction to the ban, actual behavior at 1 month after the ban, and planned future reaction beyond 1 month after the ban were compared. Oral consent was obtained from all participants, and the analytic data set was deidentified. This study was approved by the research ethics board of the University of Toronto, Toronto, Ontario, Canada. (Table) . In contrast, a larger proportion (60 [29.1%]) attempted to quit compared with only 30 (14.5%) who said they would do so. Similarly, a larger proportion (60 [29.1%]) reported using other flavored tobacco or e-cigarette products (menthol was not banned in e-cigarette products) compared with their preban plans (12 [5.8%]). After the ban, participants were less likely to anticipate using other flavored products. Of those who made a quit attempt, 16 (80.0%; 95% CI, 56.3%-92.5%) of those who primarily smoked menthol cigarettes at baseline suggested that the ban affected their decision to quit at least a little compared with 10 (25.6%; (95% CI, 14.1%-41.0%) of those who smoked menthol cigarettes only occasionally. Before the ban, 1 individual (0.3%) suggested trying to switch to marijuana and 4 (1.2%) suggested adding menthol to cigarettes separately using flavor cards, oils, or papers as substitutes for the lack of menthol, but none reported planning to use these substitutes in the future.
Discussion | This study is, to our knowledge, the first evaluation of the immediate association of a menthol cigarette ban with behavior change. Actual behaviors contrast sharply with planned behaviors. Although a substantial decrease in menthol cigarette use was observed, there was a considerable increase in use of flavored e-cigarettes and cigars. Furthermore, 29.1% of menthol smokers attempted to quit smoking shortly after ban implementation. Because previous studies 2, 3 have found an expected rate of 0.5 quit attempts and a 7.7% abstinence rate during a 6-month period in this population, this finding suggests that the ban substantially increased quit attempts. Few smokers used aftermarket additive flavorings, and there was no increase in the use of contraband tobacco. Limitations of this study include the unique demographics of menthol cigarette
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Letters smokers in Canada, where menthol cigarettes comprise 5% of cigarette sales 4,5 compared with 30% in the United S t ate s 6 a n d u s e i s n o t c o n c e nt r ate d a m o ng b l a c k Canadians. 5 The initial results suggest that removing menthol tobacco from the market is a feasible strategy that may influence cessation behavior, although differences between menthol users in Ontario, Canada, and other jurisdictions may affect the potential influence of a ban. Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Disclaimer:
The content is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health or the US Food and Drug Administration. 
Invited Commentary Local Movement to Ban Menthol Tobacco Products as a Result of Federal Inaction
The article by Chaiton et al 1 in this issue of JAMA Internal Medicine is the first empirical confirmation that banning the sale of menthol tobacco products is good for public health. The investigators surveyed individuals in Ontario, Canada, who smoked menthol cigarettes before and 1 month after the province implemented a full menthol cigarette ban on January 1, 2017. They found that 40% of menthol smokers attempted to quit smoking and 12% succeeded, substantial increases over historical levels and higher than the percentage who predicted that they would try to quit before experiencRelated article page 710 ing the ban. In addition, they found that a larger proportion (29%) reported using other flavored tobacco or e-cigarette products (menthol was not banned in e-cigarette products) compared with preban self-predictions (6%). Menthol is a particularly important additive to cigarettes because, in addition to being a flavor, it is a local anesthetic that makes it easier to inhale tobacco smoke and modulates the effects of nicotine in a way that allows tobacco companies to tune nicotine and menthol delivery to maximize nicotine's addictive effect. 2 The US Congress compromised by directing the FDA to have its new Tobacco Products Scientific Advisory Committee complete a report on "the impact of the use of menthol in cigarettes on the public health, including such use among African Americans, Hispanics, and other racial and ethnic minorities"
6 within a year to inform future regulation. The
Tobacco Products Scientific Advisory Committee completed the report within a year, concluding in July 2011 that "the removal of menthol products from the marketplace would be beneficial to the public's health." 7 Despite menthol cigarettes representing 5% of cigarette sales in Canada compared with 30% in the United States, the results of the study by Chaiton et al 1 have 2 important implications for the United States and the rest of the world. First, as predicted, eliminating menthol is good for public health because it leads to an increase in quitting. Second, it is important that flavor bans be comprehensive, including all tobacco products (such as e-cigarettes) and all flavors. There are also likely to be additional public health benefits because elimination of menthol and flavors will make cigarettes and other tobacco products less attractive and less easy to smoke for youths. In 2016, the FDA tried to limit the use of menthol and other flavors in e-cigarettes and other noncigarette tobacco products but was blocked by the Obama Administration. 8 As of January 12, 2018, the FDA had not regulated menthol in cigarettes or any other tobacco product. This failure at the federal level has spawned local action to stop the sales of menthol tobacco products. After community outreach by health advocates, town hall meetings, and work with clergy, aldermen, and women to argue that menthol products were being disproportionately marketed to black youths, in December 2013, the Chicago City Council passed the first menthol restrictions, forbidding the sale of menthol and all flavored products within 500 ft of Chicago public schools.
In June 2017, the city and county of San Francisco prohibited the sale of all flavored tobacco products, including menthol. 9 This move was too much for the tobacco industry. Shortly after Mayor Ed Lee signed the new law in San Francisco, with $700 000 from tobacco giant RJ Reynolds, a group of self-proclaimed concerned citizens and local grocers announced that they were going to force a referendum on the new law to oppose government overreach and to protect freedom of choice.
10 Their Let's Be Real San Francisco collected enough signatures to force a popular vote on the ordinance on the June 2018 ballot.
Far from a group of concerned citizens, Let's Be Real is led by a tobacco industry executive and attorneys from a law firm with longstanding ties to the industry. According to official filings, the principal officer of the committee is David Spross, not of San Francisco but of Winston-Salem, North Carolina. Spross is vice president of state government relations at tobacco company RJ Reynolds. Attorneys from the well-connected law film Nielsen Merksamer (which represents RJ Reynolds and Altria) are serving as treasurer and assistant treasurer, respectively, of the campaign.
This situation is a replay of the industry's 1983 referendum campaign to overturn San Francisco's then-new law that limits smoking in the workplace and public places. (Nielsen Merksamer worked on that one, too.) Despite being outspent more than 10 to 1, health advocates successfully defended the ordinance, which subsequently encouraged states and communities around the world to create smoke-free environments.
What about the FDA? They are still thinking about what to do, which means that meaningful action on menthol and flavors is years away, if ever.
In the meantime, as with clean indoor air and tobacco tax policy, the action will occur at the local and state levels. On the basis of the 1983 experience, a win in San Francisco could substantially accelerate the movement to end the sale of menthol and flavored tobacco products, making the FDA increasingly irrelevant.
Hypoglycemia in Hospice Patients With Type 2 Diabetes in a National Sample of Nursing Homes
Approximately one-quarter of the US population die in nursing homes, 1 where end-of-life care is of variable quality. 2 In particular, it is unknown whether patients with chronic illness, such as diabetes, continue to receive burdensome testing and treatment after transitioning to hospice care in nursing homes. Experts and the American Diabetes Association recommend relaxing glycemic control target levels for patients with diabetes and advanced disease and eventual discontinuation of medications as patients near death to avoid hypoglycemia. 3, 4 Hypoglycemia causes symptoms of weakness, diaphoresis, confusion, shakiness, and dizziness, 5 and is a potentially preventable cause of suffering among hospice patients. Whether nursing home patients with type 2 diabetes on hospice are assessed for dysglycemia, receive insulin or oral hypoglycemic medications, or experience hypoglycemia and hyperglycemia has not previously been described. Results | The study cohort included 20 329 hospice patients (Table) , 98% of whom were men (n = 19 991). Hospice patients had an 83% 100-day mortality rate (n = 16 791 deaths), and a median length of stay of 10 days. Eight percent of patients in the cohort received insulin (n = 1687). Among patients treated with insulin, mean baseline glycated hemoglobin levels were higher than patients not treated with insulin (7.4% vs 6.8%; P < .001), and the mortality rate at 100 days was lower (61% vs 85%; P < .001).
Patients treated with insulin had more frequent glucose tests (mean 1.7 glucose tests/d, vs 0.6 glucose tests/d among patients not treated with insulin; P < .001). The cumulative incidence of hypoglycemia (glucose <70 mg/dL) among all patients, accounting for the competing risk of death, was 12% at 180 days, and that of severe hypoglycemia (glucose <50 mg/dL) was 5% (Figure) . Among patients treated with insulin, 38% experienced hypoglycemia and 18% experienced severe hypoglycemia at 180 days. The highest risk of hypoglycemia occurred in the first 20 days of admission. The cumulative incidence of hyperglycemia (glucose >400 mg/dL) at 180 days was 9% in all patients, higher in the group treated with insulin (35%).
Discussion | Despite guidelines that stress avoiding hypoglycemia in hospice patients with diabetes, 4 we found that 1 in 9 nursing home patients with type 2 diabetes experienced hypoglycemia (glucose <70 mg/dL) while 1 in 20 experienced severe hypoglycemia (glucose <50 mg/dL) while on hospice. The risk of hypoglycemia was highest among patients treated with insulin, one-third of whom experienced hypoglycemia. Patients treated with insulin lived longer and experienced more hyperglycemia than patients not treated with insulin, which suggests that clinicians may be choosing to continue insulin for those hospice patients with a longer life expectancy and more severe diabetes at hospice admission. Nevertheless, hypoglycemia is not consistent with a goal of comfort, and these data demonstrate suboptimal avoidance of dysglycemia 
